BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16939815)

  • 21. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer.
    Giancola R; Olioso P; Di Riti M; Capone A; Contento A; Pompetti F; Iacone A
    Transfusion; 2008 Apr; 48(4):629-39. PubMed ID: 18208417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor.
    Laurin D; Marin V; Biagi E; Pizzitola I; Agostoni V; Gallot G; Vié H; Jacob MC; Chaperot L; Aspord C; Plumas J
    J Immunother; 2013 Apr; 36(3):181-9. PubMed ID: 23502765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.
    Introna M; Franceschetti M; Ciocca A; Borleri G; Conti E; Golay J; Rambaldi A
    Bone Marrow Transplant; 2006 Nov; 38(9):621-7. PubMed ID: 16980990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms.
    Joshi PS; Liu JQ; Wang Y; Chang X; Richards J; Assarsson E; Shi FD; Ljunggren HG; Bai XF
    J Leukoc Biol; 2006 Dec; 80(6):1345-53. PubMed ID: 16997856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.
    Tita-Nwa F; Moldenhauer G; Herbst M; Kleist C; Ho AD; Kornacker M
    Cancer Immunol Immunother; 2007 Dec; 56(12):1911-20. PubMed ID: 17487487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting CD19 with genetically modified EBV-specific human T lymphocytes.
    Roessig C; Scherer SP; Baer A; Vormoor J; Rooney CM; Brenner MK; Juergens H
    Ann Hematol; 2002; 81 Suppl 2():S42-3. PubMed ID: 12611072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The effect of tumor-dendritic cell fusion vaccines on the cytotoxicity of CIK/NK cells from cord blood].
    Li Y; Huang SL; Wu YF; Wei J; Meng Y; Zhou DH; Bao R
    Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):269-72. PubMed ID: 15949286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
    Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
    Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
    Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
    Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells.
    Zhu XL; Lin ZB
    Acta Pharmacol Sin; 2005 Sep; 26(9):1130-7. PubMed ID: 16115382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
    Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
    Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
    Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
    Cooper LJ; Al-Kadhimi Z; DiGiusto D; Kalos M; Colcher D; Raubitschek A; Forman SJ; Jensen MC
    Blood Cells Mol Dis; 2004; 33(1):83-9. PubMed ID: 15223016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
    Zhu BQ; Ju SW; Shu YQ
    Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive cellular immunotherapy with CD19-specific T cells.
    Rössig C; Pscherer S; Landmeier S; Altvater B; Jürgens H; Vormoor J
    Klin Padiatr; 2005; 217(6):351-6. PubMed ID: 16307422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phenotypic and functional characterization of NK cells in adenoids.
    Mizrahi S; Yefenof E; Gross M; Attal P; Ben Yaakov A; Goldman-Wohl D; Maly B; Stern N; Katz G; Gazit R; Sionov RV; Mandelboim O; Chaushu S
    J Leukoc Biol; 2007 Nov; 82(5):1095-105. PubMed ID: 17675561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays.
    Linn YC; Wang SM; Hui KM
    Exp Hematol; 2005 Jun; 33(6):671-81. PubMed ID: 15911091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
    Cheadle EJ; Hawkins RE; Batha H; O'Neill AL; Dovedi SJ; Gilham DE
    J Immunol; 2010 Feb; 184(4):1885-96. PubMed ID: 20089697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.